I 
117TH CONGRESS 
2D SESSION 
H. R. 7828 
To amend the Public Health Service Act to shorten the exclusivity period 
for brand name biological products from 12 to 5 years. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 18, 2022 
Ms. SCHAKOWSKY (for herself, Mr. WESTERMAN, Mr. KHANNA, Mr. DOG-
GETT, Mr. POCAN, Ms. KAPTUR, Mr. GARCI´A of Illinois, and Ms. 
DELAURO) introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act to shorten the 
exclusivity period for brand name biological products 
from 12 to 5 years. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Price Relief, Innova-
4
tion, and Competition for Essential Drugs Act’’ or the 
5
‘‘PRICED Act’’. 
6
VerDate Sep 11 2014 
16:03 May 23, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7828.IH
H7828
pamtmann on DSKBC07HB2PROD with BILLS
2 
•HR 7828 IH
SEC. 2. EXCLUSIVITY PERIOD FOR BRAND NAME BIOLOGI-
1
CAL PRODUCTS. 
2
(a) IN GENERAL.—Section 351(k)(7)(A) of the Pub-
3
lic Health Service Act (42 U.S.C. 262(k)(7)(A)) is amend-
4
ed by striking ‘‘12 years’’ and inserting ‘‘5 years’’. 
5
(b) CONFORMING CHANGES.—Paragraphs (2)(A) and 
6
(3)(A) of section 351(m) of the Public Health Service Act 
7
(42 U.S.C. 262(m)) is amended by striking ‘‘12 years’’ 
8
each place it appears and inserting ‘‘5 years’’. 
9
(c) APPLICABILITY.—This Act and the amendments 
10
made by this Act apply only with respect to a biological 
11
product for which the reference product (as such term is 
12
used in section 351 of the Public Health Service Act (42 
13
U.S.C. 262)) is licensed under subsection (a) of such sec-
14
tion on or after the date of enactment of this Act. 
15
Æ 
VerDate Sep 11 2014 
16:03 May 23, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6301
E:\BILLS\H7828.IH
H7828
pamtmann on DSKBC07HB2PROD with BILLS
